Hot on the heels of EC nod, MHRA approves Biogen's Vumerity

Biogen (Nasdaq: BIIB) today announced that the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has granted marketing authorization for Vumerity (diroximel fumarate), an oral medication to treat adults with relapsing-remitting multiple sclerosis (RRMS), adding to the European Commission authorization of diroximel fumarate earlier this week.

Diroximel fumarate is a next-generation oral fumarate with an improved tolerability profile and comparable efficacy and safety characteristics of dimethyl fumarate (Tecfidera). In the UK, approximately 130,000 people are living with MS and nearly 7,000 people are newly diagnosed each year.

“Everyone’s experience of MS is unique, it can be unpredictable and emotionally and physically challenging,” said Dr Mihaela Vlaicu, head of medical affairs, Biogen UK and Ireland. “It is important that people have MS treatment options available to them that can be easily integrated into their daily life. This new option provides flexibility for people living with MS, to be treated without having to think about dietary restrictions or when to take a dose in relation to mealtimes,” she added.